
    
      Treatment-naive HIV-infected patients are designed to enroll and receive efavirenz 400mg
      combined with tenofovir (TDF) and lamivudine (3TC) as initial antiretroviral regimens, and
      monitoring for 48 weeks, to evaluate efavirenz concentration, T-cell subsets, HIV RNA load,
      and neuropsychiatric tests with Hamilton depression scale (HAMD) and Pittsburgh sleep quality
      index (PSQI) at baseline, 4, 12, 24, 48 weeks.
    
  